Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 216.70
NAS:AVDL's Cash-to-Debt is ranked higher than
53% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. NAS:AVDL: 216.70 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:AVDL' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.08  Med: 13.98 Max: N/A
Current: 216.7
Equity-to-Asset 0.23
NAS:AVDL's Equity-to-Asset is ranked lower than
88% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:AVDL: 0.23 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:AVDL' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.32  Med: 0.51 Max: 0.8
Current: 0.23
-0.32
0.8
Interest Coverage 21.57
NAS:AVDL's Interest Coverage is ranked lower than
99.99% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:AVDL: 21.57 )
Ranked among companies with meaningful Interest Coverage only.
NAS:AVDL' s Interest Coverage Range Over the Past 10 Years
Min: 11.34  Med: 11.34 Max: 21.57
Current: 21.57
11.34
21.57
Piotroski F-Score: 3
Altman Z-Score: 1.09
Beneish M-Score: -1.75
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 13.61
NAS:AVDL's Operating Margin % is ranked higher than
69% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. NAS:AVDL: 13.61 )
Ranked among companies with meaningful Operating Margin % only.
NAS:AVDL' s Operating Margin % Range Over the Past 10 Years
Min: -635.24  Med: -30.72 Max: 41.25
Current: 13.61
-635.24
41.25
Net Margin % -5.59
NAS:AVDL's Net Margin % is ranked higher than
60% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. NAS:AVDL: -5.59 )
Ranked among companies with meaningful Net Margin % only.
NAS:AVDL' s Net Margin % Range Over the Past 10 Years
Min: -574.66  Med: -27.32 Max: 23.47
Current: -5.59
-574.66
23.47
ROE % -17.93
NAS:AVDL's ROE % is ranked lower than
73% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. NAS:AVDL: -17.93 )
Ranked among companies with meaningful ROE % only.
NAS:AVDL' s ROE % Range Over the Past 10 Years
Min: -1103.89  Med: -25.52 Max: 87.66
Current: -17.93
-1103.89
87.66
ROA % -3.70
NAS:AVDL's ROA % is ranked higher than
61% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. NAS:AVDL: -3.70 )
Ranked among companies with meaningful ROA % only.
NAS:AVDL' s ROA % Range Over the Past 10 Years
Min: -58.46  Med: -12.4 Max: 20.89
Current: -3.7
-58.46
20.89
ROC (Joel Greenblatt) % 586.69
NAS:AVDL's ROC (Joel Greenblatt) % is ranked higher than
50% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. NAS:AVDL: 586.69 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:AVDL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -662.22  Med: -49.23 Max: 3856.65
Current: 586.69
-662.22
3856.65
3-Year Revenue Growth Rate 60.40
NAS:AVDL's 3-Year Revenue Growth Rate is ranked higher than
97% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. NAS:AVDL: 60.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:AVDL' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -32.4  Med: 0.35 Max: 60.4
Current: 60.4
-32.4
60.4
3-Year EPS without NRI Growth Rate -18.20
NAS:AVDL's 3-Year EPS without NRI Growth Rate is ranked lower than
70% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. NAS:AVDL: -18.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:AVDL' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -38.2  Med: -18.2 Max: 90
Current: -18.2
-38.2
90
GuruFocus has detected 2 Warning Signs with Avadel Pharmaceuticals PLC $NAS:AVDL.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:AVDL's 30-Y Financials

Financials (Next Earnings Date: 2017-08-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

AVDL Guru Trades in

AVDL Guru Trades in

AVDL Guru Trades in

Q1 2017

AVDL Guru Trades in Q1 2017

Jim Simons 11,900 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with AVDL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412 
Compare:NAS:OTIC, NAS:ASMB, NAS:BLCM, NAS:MCRB, NAS:MYOK, NAS:CYAD, NAS:ARNA, NAS:RXDX, OTCPK:SPHDF, OTCPK:ARGNF, NAS:CLDX, NAS:MRUS, NAS:NSTG, NAS:NLNK, NAS:PDLI, NAS:BCRX, NAS:SYRS, NAS:ATRA, NAS:OVID, NAS:BSTC » details
Traded in other countries:AWK1.Germany,
Headquarter Location:Ireland
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company engaged in identifying, developing, and commercializing niche branded pharmaceutical products mainly in the U.S.

France-based Flamel Technologies focuses on improving the safety and convenience of existing drugs through its drug-delivery platforms. Flamel partners with pharma firms to develop controlled-release formulations of products in exchange for royalties. Its Micropump technology is designed to enhance small-molecule drugs, while the Medusa platform is intended for therapeutic proteins and peptides. Flamel's Micropump system is used in Coreg CR, a beta blocker marketed by GlaxoSmithKline.

Top Ranked Articles about Avadel Pharmaceuticals PLC

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
Avadel Pharmaceuticals to Report First Quarter 2017 Results
Avadel Pharmaceuticals Announces Planned Reduction of French Workforce
DUBLIN, Ireland, March 30, 2017 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), today announced a plan to reduce its headcount in France by approximately 50 people. This reduction is an effort to align the Company’s cost structure with its ongoing and future planned projects. This action does not affect the allocation of resources to its REST-ON Phase III clinical trial or any other important pipeline initiatives.
Subject to French regulatory requirements, the Company expects the reduction to be substantially completed by end of July 2017 and to incur related employee severance, benefits and other costs of approximately $2.5 to $4.0 million.  Once fully implemented, the company anticipates annual costs savings of approximately $3.5 to $4.0 million.About Avadel Pharmaceuticals plc:
Avadel Pharmaceuticals plc (NASDAQ:AVDL) is a specialty pharmaceutical company that seeks to develop differentiated pharmaceutical products that are safe, effective and easy to take through formulation development, by utilizing its proprietary drug delivery technology and in-licensing / acquiring new products; ultimately, helping patients adhere to their prescribed medical treatment and see better results. Avadel currently markets products in the hospital and primary care spaces. The Company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France. For more information, please visit www.avadel.com.Safe Harbor: This release may include "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements herein that are not clearly historical in nature are forward-looking, and the words "anticipate," "assume," "believe," "expect," "estimate," "plan," "will," "may," and the negative of these and similar expressions generally identify forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond Avadel's control and could cause actual results to differ materially from the results contemplated in such forward-looking statements. These risks, uncertainties and contingencies include the risks relating to: our dependence on a small number of products and customers for the majority of our revenues; the possibility that our Bloxiverz®, Vazculep® and Akovaz® products, which are not patent protected, could face substantial competition resulting in a loss of market share or forcing us to reduce the prices we charge for those products; the possibility that we could fail to successfully complete the research and development for pipeline products we are evaluating for potential application to the FDA pursuant to our "unapproved-to-approved" strategy, or that competitors could complete the development of such product and apply for FDA approval of such product before us; our dependence on the performance of third parties in partnerships or strategic alliances for the commercialization of some of our products; the possibility that our products may not reach the commercial market or gain market acceptance; our need to invest substantial sums in research and development in order to remain competitive; our dependence on certain single providers for development of several of our drug delivery platforms and products; our dependence on a limited number of suppliers to manufacture our products and to deliver certain raw materials used in our products; the possibility that our competitors may develop and market technologies or products that are more effective or safer than ours, or obtain regulatory approval and market such technologies or products before we do; the challenges in protecting the intellectual property underlying our drug delivery platforms and other products; our dependence on key personnel to execute our business plan; the amount of additional costs we will incur to comply with U.S. securities laws as a result of our ceasing to qualify as a foreign private issuer; and the other risks, uncertainties and contingencies described in the Company's filings with the U.S. Securities and Exchange Commission, including our annual report on Form 10-K for the year ended December 31, 2015, all of which filings are also available on the Company's website. Avadel undertakes no obligation to update its forward-looking statements as a result of new information, future events or otherwise, except as required by law.
Contacts: 
Michael F. Kanan
Chief Financial Officer
Phone:  (636) 449-1844
E-mail: [email protected]  

Lauren Stival
Sr. Director, Investor Relations and Corporate Communications
Phone:  (636) 449-5866
Email: [email protected]

Read more...
Avadel Pharmaceuticals Announces $25 Million Share Repurchase Program
DUBLIN, Ireland, March 07, 2017 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), today announced that the Company’s board of directors has authorized the repurchase of up to $25 million of the Company’s ordinary shares, represented by American Depository Shares (ADS) which are listed for trading on the NASDAQ Global Market. Repurchases may be made in open-market transactions, block transactions on or off the exchange, in privately negotiated transactions, or through other means as determined by Avadel’s board and in accordance with the regulations of the Securities and Exchange Commission.
Michael Anderson, Avadel’s Chief Executive Officer, remarked, “We ended 2016 in a strong financial position with $154.2 million of cash and marketable securities on our balance sheet. We have ample liquidity to execute our strategy, including the completion of the REST-ON Phase III trial and investment in both internal and external growth initiatives. Given our current cash position and ability to continue generating cash, we believe the timing is right to return some capital to shareholders through a repurchase program.”The timing and actual number of ADSs repurchased will depend on a variety of factors including price, trading volume, corporate, regulatory and legal requirements and market conditions.   Repurchases may also be made under a trading plan under Rule 10b5-1, which would permit ADSs to be repurchased during periods when repurchases would otherwise be prohibited due to self-imposed trading blackouts or other regulatory restrictions. The repurchase program may be suspended or discontinued at any time without notice.About Avadel Pharmaceuticals plc:
Avadel Pharmaceuticals plc (NASDAQ:AVDL) is a specialty pharmaceutical company that seeks to develop differentiated pharmaceutical products that are safe, effective and easy to take through formulation development, by utilizing its proprietary drug delivery technology and in-licensing / acquiring new products; ultimately, helping patients adhere to their prescribed medical treatment and see better results. Avadel currently markets products in the hospital and primary care spaces. The Company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France. For more information, please visit www.avadel.com.Safe Harbor: This release may include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements herein that are not clearly historical in nature are forward-looking, and the words “anticipate,” “assume,” “believe,” “expect,” “estimate,” “plan,” “will,” “may,” and the negative of these and similar expressions generally identify forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond Avadel's control and could cause actual results to differ materially from the results contemplated in such forward-looking statements. These risks, uncertainties and contingencies include the risks relating to: our dependence on a small number of products and customers for the majority of our revenues; the possibility that our Bloxiverz®,Vazculep® and Akovaz® products, which are not patent protected, could face substantial competition resulting in a loss of market share or forcing us to reduce the prices we charge for those products; the possibility that we could fail to successfully complete the research and development for pipeline products we are evaluating for potential application to the FDA pursuant to our “unapproved-to-approved” strategy, or that competitors could complete the development of such product and apply for FDA approval of such product before us; our dependence on the performance of third parties in partnerships or strategic alliances for the commercialization of some of our products; the possibility that our products may not reach the commercial market or gain market acceptance; our need to invest substantial sums in research and development in order to remain competitive; our dependence on certain single providers for development of several of our drug delivery platforms and products; our dependence on a limited number of suppliers to manufacture our products and to deliver certain raw materials used in our products; the possibility that our competitors may develop and market technologies or products that are more effective or safer than ours, or obtain regulatory approval and market such technologies or products before we do; the challenges in protecting the intellectual property underlying our drug delivery platforms and other products; our dependence on key personnel to execute our business plan; the amount of additional costs we will incur to comply with U.S. securities laws as a result of our ceasing to qualify as a foreign private issuer; and the other risks, uncertainties and contingencies described in the Company's filings with the U.S. Securities and Exchange Commission, including our annual report on Form 10-K for the year ended December 31, 2015, all of which filings are also available on the Company's website. Avadel undertakes no obligation to update its forward-looking statements as a result of new information, future events or otherwise, except as required by law.
Contacts:
Michael F. Kanan
Chief Financial Officer
Phone: (636) 449-1844
E-mail: [email protected]

Lauren Stival
Sr. Director, Investor Relations and Corporate Communications
Phone: (636) 449-5866
Email: [email protected]

Read more...

Ratios

vs
industry
vs
history
Forward PE Ratio 27.03
AVDL's Forward PE Ratio is ranked lower than
83% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 18.05 vs. AVDL: 27.03 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 7.19
AVDL's PB Ratio is ranked lower than
84% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. AVDL: 7.19 )
Ranked among companies with meaningful PB Ratio only.
AVDL' s PB Ratio Range Over the Past 10 Years
Min: 1.84  Med: 5.13 Max: 71.87
Current: 7.19
1.84
71.87
PS Ratio 2.52
AVDL's PS Ratio is ranked higher than
83% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. AVDL: 2.52 )
Ranked among companies with meaningful PS Ratio only.
AVDL' s PS Ratio Range Over the Past 10 Years
Min: 2.12  Med: 5.01 Max: 39.94
Current: 2.52
2.12
39.94
Price-to-Free-Cash-Flow 18.74
AVDL's Price-to-Free-Cash-Flow is ranked higher than
55% of the 141 Companies
in the Global Biotechnology industry.

( Industry Median: 24.99 vs. AVDL: 18.74 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
AVDL' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 4.88  Med: 19.84 Max: 154.15
Current: 18.74
4.88
154.15
Price-to-Operating-Cash-Flow 17.91
AVDL's Price-to-Operating-Cash-Flow is ranked higher than
50% of the 191 Companies
in the Global Biotechnology industry.

( Industry Median: 21.01 vs. AVDL: 17.91 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
AVDL' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.79  Med: 17.99 Max: 49.71
Current: 17.91
4.79
49.71
EV-to-EBIT 12.30
AVDL's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. AVDL: 12.30 )
Ranked among companies with meaningful EV-to-EBIT only.
AVDL' s EV-to-EBIT Range Over the Past 10 Years
Min: -54.8  Med: -9.9 Max: 13.8
Current: 12.3
-54.8
13.8
EV-to-EBITDA 7.65
AVDL's EV-to-EBITDA is ranked lower than
87% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. AVDL: 7.65 )
Ranked among companies with meaningful EV-to-EBITDA only.
AVDL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -314.7  Med: -13.2 Max: 52
Current: 7.65
-314.7
52
Current Ratio 2.43
AVDL's Current Ratio is ranked lower than
63% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. AVDL: 2.43 )
Ranked among companies with meaningful Current Ratio only.
AVDL' s Current Ratio Range Over the Past 10 Years
Min: 0.57  Med: 2.78 Max: 6.76
Current: 2.43
0.57
6.76
Quick Ratio 2.37
AVDL's Quick Ratio is ranked lower than
60% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. AVDL: 2.37 )
Ranked among companies with meaningful Quick Ratio only.
AVDL' s Quick Ratio Range Over the Past 10 Years
Min: 0.52  Med: 2.73 Max: 6.7
Current: 2.37
0.52
6.7
Days Inventory 118.64
AVDL's Days Inventory is ranked higher than
59% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. AVDL: 118.64 )
Ranked among companies with meaningful Days Inventory only.
AVDL' s Days Inventory Range Over the Past 10 Years
Min: 51.05  Med: 86.59 Max: 565.95
Current: 118.64
51.05
565.95
Days Sales Outstanding 29.51
AVDL's Days Sales Outstanding is ranked higher than
66% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. AVDL: 29.51 )
Ranked among companies with meaningful Days Sales Outstanding only.
AVDL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 14.7  Med: 69.78 Max: 100.9
Current: 29.51
14.7
100.9
Days Payable 219.43
AVDL's Days Payable is ranked higher than
82% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. AVDL: 219.43 )
Ranked among companies with meaningful Days Payable only.
AVDL' s Days Payable Range Over the Past 10 Years
Min: 180.56  Med: 228.67 Max: 865.73
Current: 219.43
180.56
865.73

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -17.30
AVDL's 3-Year Average Share Buyback Ratio is ranked lower than
66% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. AVDL: -17.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AVDL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -47.7  Med: -7.8 Max: -0.5
Current: -17.3
-47.7
-0.5

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 82.83
AVDL's Price-to-Net-Current-Asset-Value is ranked lower than
99.99% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. AVDL: 82.83 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
AVDL' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0  Med: 12.23 Max: 150.25
Current: 82.83
0
150.25
Price-to-Tangible-Book 23.12
AVDL's Price-to-Tangible-Book is ranked lower than
99% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. AVDL: 23.12 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
AVDL' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.39  Med: 4.92 Max: 577.22
Current: 23.12
1.39
577.22
Price-to-Intrinsic-Value-Projected-FCF 2.98
AVDL's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
64% of the 159 Companies
in the Global Biotechnology industry.

( Industry Median: 3.16 vs. AVDL: 2.98 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
AVDL' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0  Med: 6.57 Max: 93.64
Current: 2.98
0
93.64
Price-to-Median-PS-Value 0.50
AVDL's Price-to-Median-PS-Value is ranked higher than
80% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. AVDL: 0.50 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AVDL' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0  Med: 1.13 Max: 7.58
Current: 0.5
0
7.58
Earnings Yield (Greenblatt) % 8.14
AVDL's Earnings Yield (Greenblatt) % is ranked higher than
57% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. AVDL: 8.14 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AVDL' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 7.2  Med: 18.1 Max: 33.9
Current: 8.14
7.2
33.9

More Statistics

Revenue (TTM) (Mil) $166.5
EPS (TTM) $ -0.23
Beta2.23
Short Percentage of Float0.00%
52-Week Range $8.75 - 15.45
Shares Outstanding (Mil)41.38

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 179 132
EPS ($) 0.36 0.12
EPS without NRI ($) 0.36 0.12
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for AVDL

Headlines

Articles On GuruFocus.com
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences Apr 24 2017 
Avadel Pharmaceuticals to Report First Quarter 2017 Results Apr 17 2017 
Avadel Pharmaceuticals Announces Planned Reduction of French Workforce Mar 30 2017 
Avadel Pharmaceuticals Announces $25 Million Share Repurchase Program Mar 07 2017 
Flamel Technologies to Present at Two Upcoming Investor Conferences Jun 01 2016 
Flamel Technologies to Report First Quarter 2016 Results May 02 2016 
Flamel Technologies Receives FDA Approval of Akovaz(TM) May 02 2016 
Flamel Technologies to Present at Upcoming Investor Conferences Apr 22 2016 
Flamel Technologies Files Special Protocol Assessment for Once Nightly Sodium Oxybate Mar 31 2016 
Flamel Technologies to Present at the 28th Annual ROTH Conference Mar 08 2016 

More From Other Websites
Avadel Pharmaceuticals Supports the Narcolepsy Network's 5th Annual DREAM BIG Walk May 17 2017
Investor Network: Avadel Pharmaceuticals plc to Host Earnings Call May 09 2017
Avadel posts 1Q profit May 09 2017
Avadel Pharmaceuticals Reports First Quarter 2017 Results May 09 2017
ETFs with exposure to Avadel Pharmaceuticals Plc : May 3, 2017 May 03 2017
Avadel Pharmaceuticals Plc :AVDL-US: Earnings Analysis: Q4, 2016 By the Numbers : May 2, 2017 May 02 2017
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences Apr 24 2017
Avadel Pharmaceuticals to Report First Quarter 2017 Results Apr 17 2017
Avadel Pharmaceuticals Announces Planned Reduction of French Workforce Mar 30 2017
Avadel Pharmaceuticals Announces $25 Million Share Repurchase Program Mar 07 2017
Avadel Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Results Mar 07 2017
Avadel Pharmaceuticals (AVDL) Looks Good: Stock Up 5.3% Feb 24 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}